Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation

Bayer AG (BAYRY) announced that it has initiated a phase I study, which is evaluating its investigational highly selective GIRK4 inhibitor, BAY 3670549, for the treatment of patients with atrial fibrillation (AFib).The double-blind, placebo-controlled first-in-human dose escalation study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of BAY 3670549 in healthy participants.AFib is a common heart rhythm disorder that affects around 60 million people across the world. AFib is a notab ...